UK Competition Appeal Tribunal Overturns Abuse of Dominance Fines on Pharmaceutical Companies


The UK's Competition Appeal Tribunal has overturned a finding of abuse of dominance against Pfizer Inc. and Flynn Pharma Ltd. The ruling followed appeals by those companies against a 2016 Competition & Markets Authority decision which held the two companies had abused their respective dominant positions as the manufacturer and distributor of phenytoin sodium capsules, used to treat epilepsy. The CMA had concluded that the parties had increased the price of the drug to the National Health Service by up to 2,600% and that such pricing was excessive and abusive.



from Biotech News